Kamboh Mi

TL;DR: Apolipoprotein E (APOE) dependent lifetime risks (LTRs) for Alzheimer Disease (AD) are currently not accurately known and odds ratios alone are insufficient to assess these risks as mentioned in this paper.

TL;DR: The data show that ACT behaves as a modifier gene that alters the AD risk conventionally associated with the APOE*4 allele, and a common polymorphism in the signal peptide of ACT13 confers a significant risk for AD.

TL;DR: This is first study reporting the role of some recently emerged loci with T2D in a high risk population of Asian Indian origin and the impact of these variants on body mass index, waist to hip ratio, fasting insulin, and glucose and lipid levels using multiple linear regression analysis.

TL;DR: The authors' APOE-stratified GWAS is the first to show GWS association for AD with SNPs in the chromosome 17q21.31 region, and the finding in the stage 1 sample that AD risk is significantly influenced by the interaction of APOE with TMEM106B (P=1·6 × 10−7) is noteworthy, because TMEM 106B variants have previously been associated with risk of frontotemporal dementia.

TL;DR: A new GWAS data set from the University of Pittsburgh is used to examine in detail the recently implicated nine new regions with Alzheimer's disease (AD) risk, and a meta-analysis utilizing the top 1% GWAS single-nucleotide polymorphisms (SNPs) with P<0.01 is performed in an effort to identify new AD loci.